Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-23-082355
Filing Date
2023-03-28
Accepted
2023-03-28 17:30:27
Documents
5
Effectiveness Date
2023-03-28

Document Format Files

Seq Description Document Type Size
1 S-8 d486111ds8.htm S-8 43198
2 EX-5.1 d486111dex51.htm EX-5.1 7247
3 EX-23.2 d486111dex232.htm EX-23.2 1406
4 EX-FILING FEES d486111dexfilingfees.htm EX-FILING FEES 20963
5 GRAPHIC g486111g0328072538435.jpg GRAPHIC 2409
  Complete submission text file 0001193125-23-082355.txt   77336
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-270915 | Film No.: 23770794
SIC: 2836 Biological Products, (No Diagnostic Substances)